News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CombinatoRx, Incorporated (CRXX) Collaborator Fovea Pharmaceuticals Reports Encouraging Clinical Results with CombinatoRx-Derived Combination Drug Candidate



5/4/2009 9:49:21 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (Nasdaq Global Market: CRXX) today announced that its ophthalmics collaborator, Fovea Pharmaceuticals, reported positive results from its clinical proof-of-concept trial to assess the therapeutic effect of a CombinatoRx-derived combination drug candidate, PrednisporinTM (FOV1101), in subjects with persistent allergic conjunctivitis. Based on these data, Fovea has announced its intentions to prepare further advanced trials for PrednisporinTM both in the USA and in Europe.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES